MA71568A - Forme saline et forme cristalline de dérivé de thiénopyrimidinone - Google Patents
Forme saline et forme cristalline de dérivé de thiénopyrimidinoneInfo
- Publication number
- MA71568A MA71568A MA71568A MA71568A MA71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A MA 71568 A MA71568 A MA 71568A
- Authority
- MA
- Morocco
- Prior art keywords
- thienopyrimidinone
- derivative
- crystalline form
- salt
- salt form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C215/90—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with quaternised amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210984344 | 2022-08-16 | ||
| EP23854433.2A EP4559904A4 (fr) | 2022-08-16 | 2023-08-15 | Forme saline et forme cristalline de dérivé de thiénopyrimidinone |
| PCT/CN2023/113085 WO2024037532A1 (fr) | 2022-08-16 | 2023-08-15 | Forme saline et forme cristalline de dérivé de thiénopyrimidinone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA71568A true MA71568A (fr) | 2025-05-30 |
Family
ID=89940743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA71568A MA71568A (fr) | 2022-08-16 | 2023-08-15 | Forme saline et forme cristalline de dérivé de thiénopyrimidinone |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4559904A4 (fr) |
| JP (1) | JP7801535B2 (fr) |
| KR (1) | KR20250048100A (fr) |
| CN (1) | CN119698409A (fr) |
| AU (1) | AU2023325806A1 (fr) |
| MA (1) | MA71568A (fr) |
| WO (1) | WO2024037532A1 (fr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| TN2016000121A1 (en) * | 2013-10-07 | 2017-10-06 | Bayer Pharma AG | Cyclic thienouracil-carboxamides and use thereof |
| AU2017309015B2 (en) * | 2016-08-08 | 2022-09-15 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
| KR20210100623A (ko) * | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
| US20220288154A1 (en) * | 2019-08-08 | 2022-09-15 | ObsEva S.A. | Gnrh antagonists for the treatment of estrogen-dependent disorders |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| JP7806099B2 (ja) | 2021-02-23 | 2026-01-26 | シーエムエス・リサーチ・アンド・ディベロップメント・プライベイト・リミテッド | 縮合多環式置換5-カルボン酸チエノピリミジンジオン化合物およびその使用 |
-
2023
- 2023-08-15 MA MA71568A patent/MA71568A/fr unknown
- 2023-08-15 JP JP2025509128A patent/JP7801535B2/ja active Active
- 2023-08-15 KR KR1020257008062A patent/KR20250048100A/ko active Pending
- 2023-08-15 WO PCT/CN2023/113085 patent/WO2024037532A1/fr not_active Ceased
- 2023-08-15 AU AU2023325806A patent/AU2023325806A1/en active Pending
- 2023-08-15 CN CN202380060028.1A patent/CN119698409A/zh active Pending
- 2023-08-15 EP EP23854433.2A patent/EP4559904A4/fr active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4559904A1 (fr) | 2025-05-28 |
| AU2023325806A1 (en) | 2025-03-06 |
| CN119698409A (zh) | 2025-03-25 |
| JP7801535B2 (ja) | 2026-01-16 |
| KR20250048100A (ko) | 2025-04-07 |
| JP2025526941A (ja) | 2025-08-15 |
| WO2024037532A1 (fr) | 2024-02-22 |
| EP4559904A4 (fr) | 2025-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP3947361A4 (fr) | Sel et forme cristalline d'un inhibiteur de fak | |
| EP3453703A4 (fr) | Forme cristalline e d'un sel de tafamidis méthylglucamine, son procédé de préparation et son application | |
| EP3954693A4 (fr) | Forme cristalline d'un inhibiteur d'egfr et procédé de préparation associé | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| EP2155200A4 (fr) | Nouveau solvate et formes cristallines de dérivés de carbamoyle-cyclohexane | |
| EP4442694A4 (fr) | Nouvelle forme cristalline de trisaccharide | |
| EP3807279A4 (fr) | Sels pharmaceutiquement acceptables de sépiaptérine | |
| EP3502103A4 (fr) | Forme cristalline, type de sel d'un dérivé de 2-hydro-pyrazole substitué et son procédé de préparation | |
| EA201000104A1 (ru) | Производные пиримидина, применимые для лечения воспалительных или аллергических патологических состояний | |
| EP2431355A4 (fr) | Nouvelle forme cristalline vi de l'agomélatine son procédé de préparation et son application | |
| MA71568A (fr) | Forme saline et forme cristalline de dérivé de thiénopyrimidinone | |
| MA43549A (fr) | Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants | |
| EP3996707A4 (fr) | Formes cristallines d'inhibiteurs de la kallicréine plasmatique | |
| EP4017546A4 (fr) | Compositions et méthodes associées pour l'ablation de macrophages m2 et de cellules myéloïdes suppressives | |
| PL4013466T3 (pl) | Sposób wytwarzania tkanki chrzęstnej szklistej in vitro | |
| EP3466940A4 (fr) | Forme cristalline de l'inhibiteur du cotransporteur de sodium-glucose de type 2 | |
| IL317275A (en) | Collagen compositions and methods of use thereof | |
| EP4255431A4 (fr) | Formes solide de l'émétine | |
| EP3955911A4 (fr) | Compositions et méthodes pour inhiber la croissance de cellules sanguines cancéreuses | |
| EP4089086A4 (fr) | Forme cristalline de dérivé de pyrrolidinyl-urée et son application | |
| EP4108664A4 (fr) | Forme cristalline d'inhibiteur de jak et son application | |
| EP3744712A4 (fr) | Formes cristallines de mesaconine et procédé de préparation correspondant | |
| EP4277628C0 (fr) | Tasquinomod ou sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans le traitement du syndrome myélodysplasique | |
| EP3978486A4 (fr) | Forme cristalline d'un inhibiteur de c-met/axl |